K
Kanako Azuma
Researcher at Tokyo Medical University
Publications - 14
Citations - 376
Kanako Azuma is an academic researcher from Tokyo Medical University. The author has contributed to research in topics: Internal medicine & Medicine. The author has an hindex of 6, co-authored 10 publications receiving 325 citations.
Papers
More filters
Journal ArticleDOI
The Japanese version of the National Cancer Institute’s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE): psychometric validation and discordance between clinician and patient assessments of adverse events
Takashi Kawaguchi,Kanako Azuma,Motohiko Sano,Soan Kim,Yosuke Kawahara,Yoko Sano,Tomohide Shimodaira,Keiichiro Ishibashi,Tempei Miyaji,Ethan Basch,Takuhiro Yamaguchi +10 more
TL;DR: There is underestimation in the assessment of adverse events in Japan, and that the Japanese version of the PRO-CTCAE had acceptable reliability and validity for common and clinically important symptoms.
Journal ArticleDOI
Development and validation of the Japanese version of the Decisional Conflict Scale to investigate the value of pharmacists’ information: a before and after study
Takashi Kawaguchi,Kanako Azuma,Takuhiro Yamaguchi,Hiroshi Soeda,Yusuke Sekine,Masayoshi Koinuma,Hironori Takeuchi,Takao Akashi,Sakae Unezaki +8 more
TL;DR: Pharmacists’ provision of information was able to decrease decisional conflict among patients with cancer who were recommended a new chemotherapy regimen and the psychometric properties of the Japanese version of the Decisional Conflict Scale are considered appropriate for it to be administered to Patients with cancer.
Journal ArticleDOI
Assessment of Cancer-Related Fatigue, Pain, and Quality of Life in Cancer Patients at Palliative Care Team Referral: A Multicenter Observational Study (JORTC PAL-09)
Satoru Iwase,Takashi Kawaguchi,Akihiro Tokoro,Kimito Yamada,Yoshiaki Kanai,Yoshinobu Matsuda,Yuko Kashiwaya,Kae Okuma,Shuji Inada,Keisuke Ariyoshi,Tempei Miyaji,Kanako Azuma,Hiroto Ishiki,Sakae Unezaki,Takuhiro Yamaguchi +14 more
TL;DR: Cancer-related fatigue, considered to occur more frequently in cancer patients, was successfully assessed using patient-reported outcomes with the Brief Fatigue Inventory for the first time in Japan and suggested that fatigue is potentially as problematic as pain, which is the main reason for palliative care.
Journal ArticleDOI
Patient-generated health data collection using a wearable activity tracker in cancer patients—a feasibility study
Tempei Miyaji,Tempei Miyaji,Takashi Kawaguchi,Kanako Azuma,Shinya Suzuki,Yoko Sano,Moe Akatsu,Ayako Torii,Tadamasa Kamimura,Yuki Ozawa,Akihiko Tsuchida,Daisuke Eriguchi,Mizuha Hashiguchi,Makoto Nishino,Motohide Nishi,Yumi Inadome,Tsutomu Yamazaki,Takahiro Kiuchi,Takuhiro Yamaguchi,Takuhiro Yamaguchi +19 more
TL;DR: The feasibility of using a wearable activity tracker was confirmed in cancer patients receiving chemotherapy for a month and for future implementation in clinical trials, there is a need for further comprehensive assessment of the validity and reliability of wearable activity trackers.
Journal ArticleDOI
Palonosetron (PALO) versus granisetron (GRA) in the triplet regimen with dexamethasone (DEX) and aprepitant (APR) for preventing chemotherapy-induced nausea and vomiting (CINV) in patients (pts) receiving highly emetogenic chemotherapy (HEC) with cisplatin (CDDP): A randomized, double-blind, phase III trial.
Hironobu Hashimoto,Takeharu Yamanaka,Yasuhiro Shimada,Koji Arata,Reiko Matsui,Koichi Goto,Tomomi Takiguchi,Fumiyoshi Ohyanagi,Y. Kogure,Naoyuki Nogami,Masahiko Nakao,Koji Takeda,Kanako Azuma,Seisuke Nagase,Toshinobu Hayashi,Kimiko Fujiwara,Toshikazu Shimada,Nobuhiko Seki,Kenichi Suzuki,Nobuyuki Yamamoto +19 more
TL;DR: This study compared the efficacy of two 5-HT3drugs, PALO and GRA, in the triplet regimen to detect a 10% improvement in the overall response at the overall (0-120 hours) phase.